SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones.
"We made tremendous progress in Q3, which included the FDA authorization of AspyreRx and the completion of the work required for a commercial launch in early October. AspyreRx offers healthcare providers a clinically proven, convenient, and cost-effective treatment option that aligns with current diabetes treatment guidelines and is suitable for a broad range of people with type 2 diabetes," said Frank Karbe, Chief Executive Officer at Better Therapeutics. "Our current focus is on demonstrating commercial traction within our initial launch geographies. Securing payer coverage is a critical element for our success. We have advanced our discussions with multiple commercial payers, which gives us confidence that obtaining coverage for AspyreRx is achievable."
Third Quarter and Recent Business Highlights
- Obtained FDA Authorization: In July 2023, Better Therapeutics announced that the U.S. Food and Drug Administration (FDA) authorized AspyreRxTM (formerly BT-001) as the first prescription-only digital therapeutic (PDT) treatment indicated to provide cognitive behavioral therapy (CBT) to patients 18 years or older with type 2 diabetes (T2D). AspyreRx was reviewed through the FDA’s De Novo pathway, and its authorization creates a new class of diabetes digital behavioral therapeutic devices.
- Completed Enrollment in AspyreRx Real-world Evidence Program: In September 2023, Better Therapeutics announced the completion of enrollment of 1,000 participants in its real-world evidence program evaluating the long-term effectiveness of AspyreRx in T2D.
- New Patent Issued: In September 2023, Better Therapeutics patent - "Managing lifestyle and health interventions with predictive analytics" - was issued in the European Union (EU). This is the Company’s second patent issued of 4 patent families filed, covering the breadth of Better Therapeutics’ novel method for delivering CBT, innovative use of patient engagement data, and AI methods such as machine learning to predict outcomes and adjust treatment.
- Commercially Launched AspyreRx: In October 2023, Better Therapeutics announced the commercial launch of AspyreRx, with healthcare providers in the U.S. now able to prescribe the treatment for adults with T2D. Prescriptions are being written and patients are actively on treatment. If the patient's insurance does not cover AspyreRx, the Company is offering eligible patients a self-pay option, for a limited time, as payer coverage is established.
- LivVita Study Results Published: In October 2023, Better Therapeutics announced the pre-print publication of the results of its LivVita Liver Study in Gastro Hep Advances, a peer-reviewed journal produced by the American Gastroenterological Association (AGA). Authors concluded the totality of positive efficacy, safety, and usability data indicates the potential of Better Therapeutics’ digitally delivered CBT to help address the significant unmet clinical needs observed in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
- New Data Shows Superior Clinical Outcomes with Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes: In October 2023, Better Therapeutics announced that new data from a subgroup analysis revealed that adjunctive use of AspyreRx with standard of care, including GLP-1 receptor agonists (GLP-1), leads to a substantially greater clinical improvement compared to control participants who used GLP-1s but did not incorporate AspyreRx into their regimen.
- Showcased AspyreRx at First Promotional Meeting: In October 2023, Better Therapeutics announced its participation at the American College of Lifestyle Medicine’s 2023 Annual Meeting. At this meeting, AspyreRx was presented for the first time, allowing over 2,000 medical professionals, healthcare executives, and researchers the opportunity to experience the product firsthand and attend the sponsored education session.
- Additional Capital Raise: In October 2023, Better Therapeutics raised $2.9 million through its At-The-Market (ATM) facility, with an average price per share of $0.42. This additional capital extends the Company's financial runway into the first quarter of 2024.
Expected Upcoming Milestones
- Obtain Commercial Payer Coverage for AspyreRx: Better Therapeutics is currently engaged in advanced discussions with multiple commercial payers and expects to announce an agreement by the end of this year. The Company has submitted its Federal Supply Schedule (FSS) application and is awaiting to be assigned a contract negotiator. Once on the FSS, AspyreRx would be available to be prescribed to Veterans that receive care via the VA network.
- Request Breakthrough Device Designation: Following the successful completion of the LivVita Liver Study and publication of the results in the peer-reviewed journal Gastro Hep Advances, Better Therapeutics intends to submit a request to the FDA for Breakthrough Device Designation for its investigational PDT in MASLD and MASH by the end of 2023. Currently, there is no FDA approved treatment for MASLD and MASH, which affect approximately one in four Americans. Behavioral change is foundational to addressing the root causes of the diseases and the Company believes that a prescription treatment option could be of significant benefit to millions of patients.
- Announce a Business Development Partnership: To support the commercialization of AspyreRx, Better Therapeutics expects to announce a business development partnership by the end of this year.
- Further Strengthen Financial Position: Better Therapeutics expects to further strengthen its financial position in the fourth quarter to extend its financial runway.
Third Quarter 2023 Financial Results
Research and development expenses for the quarter ended September 30, 2023 were $1.8 million, compared to $5.5 million for the same period in 2022. The decrease was primarily due to a $2.0 million decrease in clinical study costs as a result of the completion of the BT-001 pivotal trial in the third quarter of 2022 as well as a $1.8 million decrease in personnel related costs as a result of savings from the restructuring in the first quarter of 2023 and other cost savings measures.
Sales and marketing expenses for the quarter ended September 30, 2023 were $1.4 million, compared to $1.6 million for the same period in 2022. Personnel related costs increased $0.2 million as we prepared for the commercial launch of AspyreRx. This was offset by a $0.3 million decrease in real world evidence costs as we completed enrollment in the study.
General and administrative expenses for the quarter ended September 30, 2023 were $2.1 million, compared to $4.0 million for the same period in 2022. The decrease was primarily related to a $1.1 million decline in personnel and consulting costs related to the cost savings initiatives implemented earlier this year, and a $0.7 million decrease in business insurance costs.
Interest expense, net for the quarter ended September 30, 2023 was $0.5 million, compared to $0.4 million for the same period in 2022. The increase was the result of higher interest rates associated with the Company’s secured term loan agreement with Hercules Capital.
Net loss for the quarter ended September 30, 2023 was $5.9 million, compared to $11.4 million for the same period in 2022. On a per common share basis, net loss was $0.15 and $0.48 for the quarter ended September 30, 2023 and 2022, respectively. The decline in loss per share is related to a decline in net loss in the second quarter of 2023 compared to the prior year as a result of savings from the restructuring in the first quarter of 2023 and the completion of the pivotal trial in the third quarter of 2022, and an increase in weighted average shares outstanding.
Capital resources: Cash and cash equivalents were $6.6 million on September 30, 2023, compared to $15.7 million on December 31, 2022. In October 2023, the Company raised $2.9 million in net proceeds from the utilization of our ATM facility at an average price of $0.42 per share. The proceeds from the ATM and the lower operating expenses from the restructuring in the first quarter of 2023 will extend its runway into the first quarter of 2024.
Conference Call and Webcast
Better Therapeutics will host a conference call and webcast today, November, 9, 2023, at 8:30 a.m. ET / 5:30 a.m. PT. To access the conference call, please register at: https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/dk6kxzaw. A replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: https://investors.bettertx.com.
Available Information
Better Therapeutics periodically provides other information for investors on its corporate website, http://www.bettertx.com, and its investor relations website, https://investors.bettertx.com. This includes press releases and other information about financial performance, information on corporate governance, and details related to its annual meeting of stockholders. Better Therapeutics intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Better Therapeutics’ website, in addition to following its press releases, SEC filings, and public conference calls and webcasts.
About AspyreRx
AspyreRx (formerly BT-001) was granted marketing authorization by the U.S. Food and Drug Administration (FDA) in July 2023 as the first prescription-only digital behavioral therapeutic device delivering a novel form of CBT via a smartphone to treat adults with type 2 diabetes (T2D). AspyreRx is backed by robust data demonstrating clinically meaningful and sustained reduction in A1c as well as improvements in other markers of cardiometabolic health when used up to 180 days. Using proven techniques that target the underlying psychological, behavioral, and cognitive factors that sustain or worsen T2D, AspyreRx is a self-paced, engaging experience that patients can access from their smartphone. It is prescribed by a healthcare provider in 90-day increments, with proprietary CBT delivered digitally in a weekly step-by-step process. Through interactive therapy lessons, skill-building modules, weekly goal setting and tracking, patients connect changes in behavior to improvements in blood sugar and other biometrics. Each step in the experience builds on the prior to enable and reinforce cognitive restructuring, building the emotional resilience and acceptance needed to make enduring changes.
Indications for Use
AspyreRx is a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid in the management of type 2 diabetes in patients who are under the care of a healthcare provider. AspyreRx provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address underlying factors that sustain or worsen cardiometabolic diseases. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for T2D, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding Better Therapeutics’ plans and expectations regarding FDA submissions, including a request to the FDA for Breakthrough Device Designation for its investigational PDT in MASLD and MASH, and the timing of such submissions, plans related to the commercialization of AspyreRx (formerly BT-001) for the treatment of T2D, expectations related to the efficacy and potential benefits of BT-001 and CBT and their potential treatment applications, Better Therapeutics’ plans regarding the research and advancement of its product candidates for additional treatments and other upcoming milestones, Better Therapeutics’ plans and expectations regarding the results of discussions with healthcare providers and payers and the interest of healthcare providers and payers in PDTs, the timing of and expectations related to Better Therapeutics’ engagement with Veterans Affairs and other government agencies, Better Therapeutics’ plans and expectations regarding potential financings and business development partnerships, and statements related to its cash runway and long-term plans and expectations, among others. These forward-looking statements are based on the current expectations of the management of Better Therapeutics and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to Better Therapeutics’ business, such as the willingness of the FDA to authorize PDTs, for commercial distribution and insurance companies to reimburse their use, market acceptance of PDTs, including AspyreRx, the risk that the results of previously conducted studies will not be interpreted favorably by the FDA or repeated or observed in ongoing or future studies involving Better Therapeutics’ product candidates and other risks and uncertainties included under the header “Risk Factors” in Better Therapeutics’ quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed with the Securities and Exchange Commission (SEC) on August 9, 2023, and those that are included in any of Better Therapeutics’ subsequent filings with the SEC.
BETTER THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (in thousands, except share data) |
||||||||
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2023 |
|
|
2022 |
|
||
ASSETS |
|
(unaudited) |
|
|
(audited) |
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
6,598 |
|
|
$ |
15,740 |
|
Prepaid expenses |
|
|
674 |
|
|
|
2,496 |
|
Other current assets |
|
|
73 |
|
|
|
210 |
|
Total current assets |
|
|
7,345 |
|
|
|
18,446 |
|
|
|
|
|
|
|
|
||
Capitalized software development costs, net |
|
|
2,792 |
|
|
|
3,888 |
|
Property and equipment, net |
|
|
102 |
|
|
|
121 |
|
Other long-term assets |
|
|
483 |
|
|
|
488 |
|
Total Assets |
|
$ |
10,722 |
|
|
$ |
22,943 |
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
2,308 |
|
|
$ |
3,035 |
|
Accrued payroll |
|
|
1,886 |
|
|
|
2,301 |
|
Other accrued expenses |
|
|
2,158 |
|
|
|
3,626 |
|
Current portion of long-term debt |
|
|
6,586 |
|
|
|
4,532 |
|
Total current liabilities |
|
|
12,938 |
|
|
|
13,494 |
|
Long-term debt, net of current portion and debt issuance costs |
|
|
7,721 |
|
|
|
10,348 |
|
Total liabilities |
|
|
20,659 |
|
|
|
23,842 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' deficit: |
|
|
|
|
|
|
||
Common stock |
|
|
4 |
|
|
|
2 |
|
Additional paid-in capital |
|
|
124,370 |
|
|
|
110,602 |
|
Accumulated deficit |
|
|
(134,311 |
) |
|
|
(111,503 |
) |
Total Stockholders' Deficit |
|
|
(9,937 |
) |
|
|
(899 |
) |
Total Liabilities and Stockholders’ Deficit |
|
$ |
10,722 |
|
|
$ |
22,943 |
|
BETTER THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
September 30, |
|
|
September 30, |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
1,833 |
|
|
$ |
5,477 |
|
|
$ |
7,462 |
|
|
$ |
13,391 |
|
Sales and marketing |
|
|
1,392 |
|
|
|
1,557 |
|
|
|
5,200 |
|
|
|
5,284 |
|
General and administrative |
|
|
2,116 |
|
|
|
3,962 |
|
|
|
8,629 |
|
|
|
11,265 |
|
Total operating expenses |
|
|
5,341 |
|
|
|
10,996 |
|
|
|
21,291 |
|
|
|
29,940 |
|
Loss from operations |
|
|
(5,341 |
) |
|
|
(10,996 |
) |
|
|
(21,291 |
) |
|
|
(29,940 |
) |
Interest expense, net |
|
|
(518 |
) |
|
|
(406 |
) |
|
|
(1,512 |
) |
|
|
(1,052 |
) |
Loss before provision for income taxes |
|
|
(5,859 |
) |
|
|
(11,402 |
) |
|
|
(22,803 |
) |
|
|
(30,992 |
) |
Provision for income taxes |
|
|
3 |
|
|
|
3 |
|
|
|
5 |
|
|
|
3 |
|
Net loss |
|
$ |
(5,862 |
|
$ |
(11,405 |
) |
|
$ |
(22,808 |
) |
|
$ |
(30,995 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.15 |
) |
|
$ |
(0.48 |
) |
|
$ |
(0.73 |
) |
|
$ |
(1.32 |
) |
Weighted-average shares used in computing net loss per share |
|
|
38,495,150 |
|
|
|
23,693,154 |
|
|
|
31,214,093 |
|
|
|
23,533,290 |
|
